BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital

Show simple item record

dc.contributor University of Helsinki, Department of Pathology en
dc.contributor University of Helsinki, Department of Pathology en
dc.contributor University of Helsinki, Department of Surgery en
dc.contributor University of Helsinki, Department of Oral and Maxillofacial Diseases en
dc.contributor University of Helsinki, Medicum en
dc.contributor.author Kelppe, Jetta
dc.contributor.author Thoren, Hanna
dc.contributor.author Ristimäki, Ari
dc.contributor.author Haglund, Caj
dc.contributor.author Sorsa, Timo
dc.contributor.author Hagström, Jaana
dc.date.accessioned 2020-03-05T03:14:34Z
dc.date.available 2021-06-16T02:47:18Z
dc.date.issued 2019-05
dc.identifier.citation Kelppe , J , Thoren , H , Ristimäki , A , Haglund , C , Sorsa , T & Hagström , J 2019 , ' BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital ' , Oral Diseases , vol. 25 , no. 4 , pp. 1169-1174 . https://doi.org/10.1111/odi.13072 en
dc.identifier.issn 1354-523X
dc.identifier.other PURE: 124670783
dc.identifier.other PURE UUID: e404919a-b775-4154-9854-5ff70a88a6b4
dc.identifier.other WOS: 000465105300022
dc.identifier.other ORCID: /0000-0001-6079-7881/work/57544390
dc.identifier.uri http://hdl.handle.net/10138/312881
dc.description.abstract Objectives We aimed to investigate BRAF V600E percentage immunohistochemically in ameloblastomas of a single institute cohort. We were interested if age, location, histological properties, or tumor recurrence depend on the BRAF status. Subjects, materials and methods We had 36 formalin-fixed, paraffin-embedded ameloblastoma tissue samples of patients treated at the Helsinki University Hospital between the years 1983-2016. Tissue sections underwent immunohistochemistry by Ventana BenchMark XT immunostainer using Ms Anti-Braf V600E (VE1) MAB. We used R 3.4.2 and RStudio 1.1.383 to conduct statistical analysis for BRAF positivity and earlier onset as well as tumor location. We used chi-squared tests and 2-by-2 table functions to determine connections between BRAF positivity and recurrence, growth pattern, and type. Results BRAF-positive tumors occurred in younger patients compared to BRAF-negative tumors (p = 0.015) and they located mostly to the mandible (p <0.001). Growth patterns were limited to two in BRAF-negative tumors when BRAF-positive tumors presented with one to four growth patterns (p = 0.02). None of the maxillary tumors showed BRAF positivity and of these, 72.2% recurred. Conclusions An immunohistochemical BRAF marker could be a beneficial tool to predict the outcome of patients with this aggressive, easily recurring tumor. en
dc.format.extent 6
dc.language.iso eng
dc.relation.ispartof Oral Diseases
dc.rights en
dc.subject ameloblastoma en
dc.subject BRAF en
dc.subject immunohistochemistry en
dc.subject MUTATIONS en
dc.subject 313 Dentistry en
dc.subject 3126 Surgery, anesthesiology, intensive care, radiology en
dc.title BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital en
dc.type Article
dc.description.version Peer reviewed
dc.identifier.doi https://doi.org/10.1111/odi.13072
dc.type.uri info:eu-repo/semantics/other
dc.type.uri info:eu-repo/semantics/acceptedVersion
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl

Files in this item

Total number of downloads: Loading...

Files Size Format View
BRAF_V600E_expr ... ki_University_Hospital.pdf 901.8Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record